487 related articles for article (PubMed ID: 17973539)
1. Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.
De Backer D
Drug Saf; 2007; 30(11):995-1010. PubMed ID: 17973539
[TBL] [Abstract][Full Text] [Related]
2. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
[TBL] [Abstract][Full Text] [Related]
3. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
Ely EW; Laterre PF; Angus DC; Helterbrand JD; Levy H; Dhainaut JF; Vincent JL; Macias WL; Bernard GR;
Crit Care Med; 2003 Jan; 31(1):12-9. PubMed ID: 12544987
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis.
Kanji S; Devlin JW; Piekos KA; Racine E
Pharmacotherapy; 2001 Nov; 21(11):1389-402. PubMed ID: 11714212
[TBL] [Abstract][Full Text] [Related]
5. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
Bernard GR; Margolis BD; Shanies HM; Ely EW; Wheeler AP; Levy H; Wong K; Wright TJ;
Chest; 2004 Jun; 125(6):2206-16. PubMed ID: 15189943
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of recombinant human activated protein C for severe sepsis.
Bernard GR; Vincent JL; Laterre PF; LaRosa SP; Dhainaut JF; Lopez-Rodriguez A; Steingrub JS; Garber GE; Helterbrand JD; Ely EW; Fisher CJ;
N Engl J Med; 2001 Mar; 344(10):699-709. PubMed ID: 11236773
[TBL] [Abstract][Full Text] [Related]
7. Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.
McCoy C
Expert Opin Drug Saf; 2004 Nov; 3(6):625-37. PubMed ID: 15500421
[TBL] [Abstract][Full Text] [Related]
8. Risk-benefit analysis for drotrecogin alfa (activated).
Schein RM; Kinasewitz GT
Am J Surg; 2002 Dec; 184(6A Suppl):S25-38. PubMed ID: 12521615
[TBL] [Abstract][Full Text] [Related]
9. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
Ridley S; Lwin A; Wyncoll D; Lippett S; Watson D; Gunning K; Higgins D
Eur J Anaesthesiol; 2008 Mar; 25(3):211-6. PubMed ID: 18031590
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.
Kalil AC; LaRosa SP
Lancet Infect Dis; 2012 Sep; 12(9):678-86. PubMed ID: 22809883
[TBL] [Abstract][Full Text] [Related]
11. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
[TBL] [Abstract][Full Text] [Related]
12. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
Barton P; Kalil AC; Nadel S; Goldstein B; Okhuysen-Cawley R; Brilli RJ; Takano JS; Martin LD; Quint P; Yeh TS; Dalton HJ; Gessouron MR; Brown KE; Betts H; Levin M; Macias WL; Small DS; Wyss VL; Bates BM; Utterback BG; Giroir BP
Pediatrics; 2004 Jan; 113(1 Pt 1):7-17. PubMed ID: 14702440
[TBL] [Abstract][Full Text] [Related]
13. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C.
Yan SB; Nelson DR
Crit Care Med; 2004 May; 32(5 Suppl):S239-46. PubMed ID: 15118525
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated).
Rudis MI; Fish DN
Pharmacotherapy; 2002 Dec; 22(12 Pt 2):182S-195S. PubMed ID: 12492225
[TBL] [Abstract][Full Text] [Related]
15. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis.
Bernard GR
Crit Care Med; 2003 Jan; 31(1 Suppl):S85-93. PubMed ID: 12544981
[TBL] [Abstract][Full Text] [Related]
16. Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.
McCoy C; Matthews SJ
Clin Ther; 2003 Feb; 25(2):396-421. PubMed ID: 12749504
[TBL] [Abstract][Full Text] [Related]
17. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.
Green C; Dinnes J; Takeda A; Shepherd J; Hartwell D; Cave C; Payne E; Cuthbertson BH
Health Technol Assess; 2005 Mar; 9(11):1-126, iii-iv. PubMed ID: 15774234
[TBL] [Abstract][Full Text] [Related]
18. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.
Dhainaut JF; Laterre PF; Janes JM; Bernard GR; Artigas A; Bakker J; Riess H; Basson BR; Charpentier J; Utterback BG; Vincent JL;
Intensive Care Med; 2003 Jun; 29(6):894-903. PubMed ID: 12712239
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.
Barie PS; Hydo LJ; Shou J; Eachempati SR
Surg Infect (Larchmt); 2006; 7 Suppl 2():S77-80. PubMed ID: 16895513
[TBL] [Abstract][Full Text] [Related]
20. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.
Bernard GR; Macias WL; Joyce DE; Williams MD; Bailey J; Vincent JL
Crit Care; 2003 Apr; 7(2):155-63. PubMed ID: 12720562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
